110 results about "Cachexia" patented technology

The invention provides an aromatic fused ring compound, a pharmaceutical composition containing the compound and application of the aromatic fused ring compound, and relates to the technical field of medicines. The aromatic fused ring compound disclosed by the invention has a structure as shown in a formula (I): # imgabs0 # or a stereoisomer and pharmaceutically acceptable salt thereof, wherein the structural unit # imgabs1 # is selected from # imgabs2 # or # imgabs3 #, and each substituent group is defined in the specification. The aromatic fused ring compound has a strong inhibition effect on SIKs enzyme activity, has a positive regulation effect on TNF-alpha and IL-10 in serum of mice with acute inflammation, has a longer half-life period and a higher oral exposure amount, has a remarkable inhibition effect on NF-kappa B gene expression of THP-1 cells under MDP stimulation, and can be used for preparing medicines for treating acute inflammation. The traditional Chinese medicine composition has a remarkable weight recovery promoting effect on cachexia induced by cis-platinum.

The invention discloses a 7-azaindole compound as well as a preparation method and application thereof, belongs to the field of medicine synthesis, and particularly relates to a pyrazole or indole substituted 7-azaindole compound as shown in a general formula (I) as well as a preparation method and application thereof in medicine. According to the compound disclosed by the invention, tumor cachexia skeletal muscle atrophy is relieved by inhibiting ActRIIB protein in an MSTN pathway, and a remarkable tumor cachexia resisting effect is achieved. Experimental results show that the compound has good anti-cachexia activity and can be further used for preparing novel anti-cachexia drugs. # imgabs0 #

The present invention relates to a GFRAL-antagonistic antibody and a use thereof, and more particularly, to an anti-GFRAL antibody comprising a heavy chain CDR and a light chain CDR of specific sequences, and an antigen-binding fragment thereof. The anti-GFRAL antibody is expected to be usefully utilized for ameliorating or treating anorexia-cachexia syndrome associated with cancer, and adverse effects of chemotherapeutic drugs.

The invention discloses a Chinese medicine composition for improving muscle atrophy caused by tumor cachexia, a preparation method and an application thereof. The Chinese medicine composition is mainly composed of the following raw materials by weight: 25-35g of Astragalus, 8-14g of Angelica, 8-14g of White Peony, 6-8g of Licorice, 8-14g of Cinnamomum Cassia, 8-14g of Epimedium, 10-12g of Morinda Officinalis, 18-22g of Agrimoniae, 8-12g of Jujube, 8-14g of Rhizoma Anemarrhenae, 5-8g of Phellodendron, 6-10g of Paris Polygoni Multiflori, 18-22g of Caulis Sargentodoxae, and 18-22g of Caulis Spatholobi. The Chinese medicine composition of the invention uses pure natural Chinese medicine raw materials, has a wide range of raw material sources, has no toxic side effects, can effectively improve the situation of muscle atrophy in patients with tumor cachexia, prevent and treat weight loss in lung cancer cachexia, improve the therapeutic effect and quality of life of tumor patients, and prolong the survival time of patients. It is a major innovation in treating tumor cachexia with Chinese medicine.

A composition comprising a naphthoquinone-based compound as an active ingredient and uses thereof are disclosed. The composition is effective for preventing or ameliorating fatigue, cachexia, pain, cognitive decline, and hematopoietic stem cell reduction which are side effects related to anticancer drug treatment. The naphthoquinone-based compounds, dunnione and β-lapachone, reduce the secretion and production of inflammatory cytokines which are increased by the anticancer drug treatment, and prevent fatigue, cachexia, cognitive decline, and hematopoietic stem cell reduction which are side effects associated with anticancer drug treatment.

The present invention relates to a method for improving muscle strength, and / or muscle mass by administering a composition containing as an active ingredient at least one selected from the group consisting of Akkermansia muciniphila cells, a culture thereof and a lysate thereof, and a method for preventing or treating muscle diseases where muscle strength and / or mass is weakened by sarcopenia, cachexia or muscle wasting.

The invention relates to an application of an amide substituted 2-oxopyridine compound. Specifically, a compound of formula (I), or a pharmaceutically acceptable salt, a solvate, an optically pure isomer, a stereoisomer or a mixture thereof, is used for preparing a medicine or a preparation, and the medicine or the preparation is used for one or more of the following applications: (a) a medicine for treating and / or preventing cachexia-related diseases, (b) a medicine for treating and / or preventing cachexia-related diseases, (c) a medicine for treating and / or preventing cachexia-related diseases, and (c) a medicine for treating and / or preventing cachexia-related diseases; (b) inhibiting the browning of fat cells; and / or (c) promoting the degradation of the PRDM16 protein; wherein the compound shown in the formula (I) has a structure shown in the specification,

The present invention relates to novel use of a cathepsin L inhibitor Z-Phe-Tyr-CHO (C26H26N2O5), wherein the cathepsin L inhibitor Z-Phe-Tyr-CHO inhibits cancer progression and cachexia and muscle damage that are caused by cancer, and thus can be effectively used for preventing, ameliorating or treating cachexia and muscle loss, while having anticancer activity.

The invention discloses a marker for combined diagnosis of pancreatic cancer cachexia. The research finds that the serum pancreatic cancer exosome miR-203a-3p can be used for diagnosing pancreatic cancer cachexia or early stage of pancreatic cancer cachexia independently or in combination with nutrition inflammation indexes, and has relatively high diagnosis efficiency, and the diagnosis efficiency is greatly improved after the miR-203a-3p is combined with other indexes; a new direction is provided for effective diagnosis and treatment of pancreatic cancer cachexia or precachexia of pancreatic cancer, and the application prospect is wide.

The present application relates to a kind of water gel based on crude polysaccharide of Radix Trichosanthis and its preparation method and application.The water gel based on crude polysaccharide of Radix Trichosanthis is prepared by the following method:1) preparing crude polysaccharide of Radix Trichosanthis;2) making aldehyde group of crude polysaccharide of Radix Trichosanthis to obtain aldehyde group of crude polysaccharide of Radix Trichosanthis;And 3) aldehyde group of crude polysaccharide of Radix Trichosanthis and carboxymethyl cellulose are covalently combined to form the water gel by Schiff base reaction.The multifunctional water gel of the present application is expected to become the candidate dressing of clinical protection and treatment of cachexia wound and other immunosuppressive chronic wound.

Nucleotide sequences including a micro-dystrophin gene are provided. The micro-dystrophin genes may be operatively linked to a regulatory cassette. Methods of treating a subject having, or at risk of developing, muscular dystrophy, sarcopenia, heart disease, or cachexia are also provided. The methods may include administering a pharmaceutical composition including the micro-dystrophin gene and a delivery vehicle to a subject. Further, the methods may include administering the pharmaceutical composition a subject having Duchenne muscular dystrophy or Becker muscular dystrophy.

Human relaxin-2 as active ingredient in a pharmaceutical composition for treating a subject suffering from cachexia syndrome or cardiac wasting or suspected of being at risk of suffering from cardiac wasting or cardiac decompensation is described. Also described are methods of diagnosis of cachexia and cardiac wasting and patients suspected of being at risk of suffering from cardiac decompensation. Further described is a patch pump for sc. or iv infusion of relaxin or human relaxin-2.

The present invention relates to a method for treating conditions associated with weight loss in emaciation and cachexia with a probiotic composition and the use of a probiotic composition in the treatment of conditions associated with weight loss in emaciation and cachexia. The present invention provides a method of treating a condition associated with weight loss, the method comprising administering to a subject considered in need of such treatment a probiotic composition wherein the composition comprises at least two bacteria, each preferably selected from a different genus, the genus is preferably selected from the group consisting of Lactobacillus genus, Enterococcus genus and Bifidobacterium genus. The present invention also provides a probiotic composition for use in the treatment of a subject suffering from a condition associated with weight loss wherein the composition comprises at least two bacteria each preferably selected from a different genus, preferably selected from the group consisting of Lactobacillus genus, Enterococcus genus and Bifidobacterium genus.

Human relaxin-2 as active ingredient in a pharmaceutical composition for treating a subject exhibiting cachexia syndrome or cardiac wasting or cardiac decompensation. The application also describes methods of treating cachexia, cardiac wasting and patients exhibiting clinical signs of suffering from cardiac decompensation. Further described is a method of using a patch pump for subcutaneous or intravenous infusion of relaxin or human relaxin-2.

To provide Akt3 modulators and compounds and pharmaceutical compositions for treating diseases by modulation of Akt3 signaling.SOLUTION: A compound of Formula Ib or Ic, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound for treating a disease in a subject in need thereof, A pharmaceutical composition wherein the treatment comprises administering to a subject an effective amount of the compound; optionally wherein the disease is selected from the group consisting of neurodegenerative diseases, cachexia, eating disorders, obesity, complications of obesity, inflammatory diseases, virally-induced inflammatory reactions, Gulf War Syndrome, tuberous sclerosis, retinitis pigmentosa, graft rejection, cancer, autoimmune diseases, ischemic tissue injury, traumatic tissue injury and combinations thereof.SELECTED DRAWING: Figure 6

The application provides application of ABT199 in preparation of a drug for treating muscle atrophy. Compared with the prior art, the application provides a new use of ABT199 in treating muscle atrophy. Experimental research proves that ABT199 administration can significantly restore the exercise capacity of a cachexia-induced muscle atrophy mouse, improve the muscle cross-sectional area of the mouse, restore the reduced glutathione content of the mouse, and improve the superoxide dismutase activity, so as to improve the muscle atrophy phenotype of the mouse and muscle atrophy-related biochemical indexes. ABT199 can significantly restore cell muscle atrophy-related gene and protein expression, and improve the cachexia-induced muscle atrophy phenotype by reducing related inflammatory mediators; ABT199 can significantly improve the mitochondrial membrane potential, increase the expression of mitochondrial neogenesis-related genes, and reduce the production of active oxygen.

Inhibitory nucleic acid molecules are provided as well as methods of use thereof. Specifically, the disclose provides an Inhibin BetaA (inhba) inhibitory nucleic acid molecule, which is an antisense oligonucleotide, siRNA, or shRNA. Further disclosed are sequences that are targeted by the inhba inhibitory nucleic acid molecule; and methods of treating a disease or disorder in a subject comprising administering an inhba inhibitory nucleic acid molecule to the subject, wherein the disease or disorder is selected from the group consisting of cancers, autoimmune diseases, fibrotic disorders, blood disorders, allergies and allergic diseases, heart failure, neurodegenerative diseases, cachexia and inflammatory diseases.

The invention provides an application of O-demethylangorapin in preparation of a medicine for relieving renal toxicity and myotoxicity of cis-platinum and cachexia manifestation caused by the renal toxicity and the myotoxicity of the cis-platinum. The active ingredient of the medicine is one or more of O-demethylated angorapin, a hydrate of the O-demethylated angorapin, a pharmaceutically acceptable salt of the O-demethylated angorapin, a tautomer of the O-demethylated angorapin, a stereoisomer of the O-demethylated angorapin and a precursor compound of the O-demethylated angorapin. The O-demethylangiecarpin has the potential to be developed into a drug for relieving the toxicity of cis-platinum.

To provide a new compound useful for treating cachexia or wasting syndrome which is a severe complication of chronic diseases such as neurodegenerative diseases and cancer.SOLUTION: Compounds of formula Ib or Ic are described. The compounds can modify the Akt3 or effects of nature in vitro or in vivo, and can also be used, alone or in combination with other agents, in the prevention or treatment of various conditions.SELECTED DRAWING: Figure 1

The invention relates to the technical field of medical health, in particular to an intelligent evaluation and intervention system for muscle quality of a patient with advanced solid tumors. The multi-dimensional dynamic evaluation unit is used for forming the extracted somatic cell mass, the score of the anorexia-cachexia syndrome, the standardized skeletal muscle index and the average muscle radiation attenuation value into multi-dimensional feature data, and the multi-dimensional dynamic evaluation unit is used for evaluating the quality of the somatic cells on the basis of the multi-dimensional feature data and fusing tumor treatment scheme data. Generating a multi-dimensional muscle health index and a malignant fluid risk probability through a decision tree model, and dividing patients into different risk levels; and the intervention strategy generation unit is used for outputting a comprehensive intervention scheme based on the multi-dimensional muscle health index and the malignant fluid risk probability in combination with the real-time tolerance data and the risk level of the patient. According to the system, the L3 level skeletal muscle index and the muscle radiation attenuation value can be extracted more accurately and stably, manual annotation and manual variation are reduced, and the reliability of image quantification is improved.

Described herein are treatment regimens, therapies, pharmaceutical formulations and methods of using quercetin to prevent, treat, and / or protect from muscle wasting including 1) sarcopenia associated with aging; and 2) cachexia associated with chronic diseases and their treatments including but not limited to cancer, cardiovascular disease, chronic obstructive pulmonary disease (COPD), HIV, and kidney disease.

The present invention relates to a pharmaceutically acceptable acid addition salt comprising: (i) S-indolylcarbamate; and (ii) an organic acid, wherein the organic acid has: a pKa1 greater than or equal to 2.5; and a chemical formula of CxHy(CO2H)z, wherein x is 1 to 10, y is 2 to 20, and z is 1 or 2. The pharmaceutically acceptable acid addition salt is used to treat conditions such as cachexia, sarcopenia, neuromuscular disorders, and muscle weakness.

The application provides a kinase inhibitor leading compound, a virtual screening method thereof and application of the kinase inhibitor leading compound in preparation of branched-chain alpha-keto acid dehydrogenase kinase inhibitors and / or drugs for treating diseases mediated by branched-chain alpha-keto acid dehydrogenase kinase. The virtual screening method provided by the application combines various virtual screening platforms to screen a large-scale compound library, improves the true positive rate of screening results, reduces the number of compounds needing experimental screening, and saves screening time and cost. In addition, the compounds I-III screened out with good binding affinity to BCKDK can be used in researches on targeting BCKDK to treat major diseases such as obesity, insulin resistance, maple syrup urine disease, neurological dysfunction, liver cancer, colorectal cancer and tumor cachexia.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for preventing and treating tumor cancer and resisting relapse, which comprises the following raw materials in parts by weight: 1-50 parts of sanqi, 1-50 parts of Chinese mahonia, 10-100 parts of gynostemma pentaphylla, 1-50 parts of wild poria cocos, 1-50 parts of local scorpion and 1-60 parts of wild gastrodia elata. The whole formula is synergistic, and the cachexia metabolic disorder is improved by adjusting the intestinal flora-immune axis; the traditional Chinese medicine composition integrates three treatment methods of promoting blood circulation to remove blood stasis, clearing away heat and toxic materials and supporting healthy energy, eliminates evil without hurting healthy energy through multi-channel cross regulation and control, and provides a traditional Chinese medicine innovative scheme for tumor prevention and treatment.

The invention provides application and an application method of nucleic acid in preparation of a medicine for preventing and treating malignant fluid. According to the nucleic acid disclosed by the invention, in-vivo malignant fluid related factors are regulated through oligonucleotides contained or generated by the nucleic acid, an autologous reprogramming state is started, and by regulating activity / silence of key nucleic acid factors, a non-coding RNA regulation and control signal programming network is realized, and the purpose of regulating and controlling a plurality of signal channels by a single non-coding RNA is realized; and thus, a new steady state of the maladjustment physiological state is reconstructed. Compared with other nucleic acid drugs, the drug taking the nucleic acid as the active component has the advantages that the dosage is extremely small in the prevention and treatment process, the drug safety is ensured on the basis of achieving the drug effect, and the current situation of traditional plasmid / nucleic acid drug administration is subverted. In addition, the nucleic acid provided by the invention has no specific reaction, and has relatively high in-vivo safety.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for replenishing qi, enriching blood, tonifying spleen and nourishing kidney as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 2 to 12 parts of radix angelicae sinensis, 5 to 20 parts of radix codonopsis, 5 to 20 parts of radix astragali seu hedysari, 2 to 12 parts of rhizoma atractylodis macrocephalae, 2 to 15 parts of poria cocos, 3 to 13 parts of colla corii asini, 3 to 13 parts of tortoise-shell glue, 2 to 12 parts of herba cistanche, 5 to 15 parts of radix rehmanniae praeparata, 3 to 15 parts of rhizoma polygonati, 3 to 13 parts of herba epimedii, 2 to 12 parts of fructus crataegi, 5 to 15 parts of arillus longan, 2 to 12 parts of fructus ligustri lucidi, 2 to 6 parts of fructus schisandrae chinensis and 1 to 5 parts of cortex cinnamomi. The traditional Chinese medicine composition has the main effects of replenishing qi, enriching blood, tonifying spleen and nourishing kidney, is used for rehabilitation after cancer surgery or chemotherapy and used for resisting cancer relapse, is particularly used for patients with spleen and kidney deficiency type cachexia after cancer surgery or chemotherapy, and improves the problems of emaciation, insomnia, inappetence, mental fatigue and tiredness and the like of the patients with the patients with the spleen and kidney deficiency type cachexia after cancer surgery or chemotherapy.

The present invention provides a GDF15-binding nanoantibody, and a use thereof in preparation of a drug for treating tumor cachexia and in detection of GDF15. The nanoantibody provided in the present invention exhibits high affinity for GDF-15 and is capable of blocking the binding of GDF-15 to GFRAL.

The invention relates to an iodinated CT contrast agent for non-invasive diagnosis of cachexia. This is possible by superior resolution of CT combined with CT contrast agent specific for the brown and / or beige adipose tissue (BAT).

The present invention discloses a traditional Chinese medicine, Moutanpi (Moutan radicis cort), which has potential use in preventing or treating cachexia and muscle loss in cancer patients. The composition is a novel treatment for cachexia.